DAUNORUBICIN (BRD-A68009927)
Overview
- pert_id
- BRD-A68009927
- Name
- daunorubicin
- Synonyms
- daunomycin; S3035
- Collection
- BIOA
- Summary
- Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.
- MOA
- RNA synthesis inhibitor, topoisomerase inhibitor
- Target(s)
- TOP2A, TOP2B
- Indication(s)
- acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)
- Phase
- Launched
- Canonical SMILES
- COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](OC5CC(N)C(O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)C
- InChI key
- InChIKey=STQGQHZAVUOBTE-JYZNYWJRSA-N
- InChI string
- InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10?,14?,16-,17?,22?,27-/m0/s1
- Molecular formula
- C27H29NO10
- Molecular weight
- 527.52
External links
- PubChem
- 3085107
- Wikipedia
- http://en.wikipedia.org/wiki/Daunorubicin
- SEP-L1000
- BRD-A68009927
Predicted MOAs
| MOA | Probability |
|---|---|
| topoisomerase inhibitor | 0.9916 |
| HSP inhibitor | 0.0009 |
| tubulin polymerization inhibitor | 0.0009 |
| protein synthesis inhibitor | 0.0007 |
| retinoid receptor agonist | 0.0007 |
| MEK inhibitor | 0.0006 |
| CDK inhibitor | 0.0004 |
| EGFR inhibitor | 0.0004 |
| NFkB pathway inhibitor | 0.0003 |
| adrenergic receptor antagonist | 0.0003 |
Chemical structure
Diagnoses (based on Mount Sinai EHR)
Top diagnoses associated with daunorubicin:
Co-prescribed Drugs (based on Mount Sinai EHR)
Top coprescribed drugs of daunorubicin:
Age Distribution (based on Mount Sinai EHR)
Probability distribution for the prescription of daunorubicin across different ages: